Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
2.
researchsquare; 2023.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2842047.v1

ABSTRACT

Machine learning (ML) methods are used in genomics studies for elucidation of three-dimensional structure of chromatin in genome. In chromatin, the formation of loop in 3D structure, controls the expression of specific genes in transcription and replication level. There is a 100% sequence similarity between SARS CoV2 and human genome for seventy-one nucleotide sequence in chromosome 2. This short stretch of nucleotide sequence has been thoroughly analyzed with the help of UCSC Genome Brower. A few machine learning models for construction of 3D structure of human genome for this specific chromosomal region have been explored. In the specific chromosomal region, the presence of a protein coding gene (KCNJ3), enhancer, promoter and LTR region are identified. With the help of machine learning methods, the loop formation on the genome structure has been conformed. Topologically Associating Domains (TADs) in this specific chromosomal region are also predicted. The loop formation along the chromosomal region facilitates the binding of RNA polymerase II and CTCF in the promoter region of KCNJ3 gene. During transcription of KCNJ3 gene, epigenetic control of this gene expression occurs through acetylation in histone protein present in nucleosome complex. Thus, the rate of gene expression of KCNJ3 gene increases, which rises the K+ concentration inside the cells, resulting in hypokalemia in blood serum of COVID-19 patients.


Subject(s)
COVID-19 , Hypokalemia
3.
PLoS One ; 17(7): e0271132, 2022.
Article in English | MEDLINE | ID: covidwho-2021864

ABSTRACT

BACKGROUND: Hypokalemia is a frequent electrolyte imbalance in patients with COVID-19. The aim of this study was to estimate the association between hypokalemia and clinical prognosis in patients with moderate COVID-19. METHODS: A single-center, retrospective, observational study was conducted on 81 non-ICU admitted patients with moderate COVID-19 according to the criteria issued by the Chinese Health Bureau in the Third People's Hospital of Yangzhou (Northern Jiangsu People's Hospital New District Branch) from 4th to 25th August 2021. The demographic, clinical, and laboratory data were reviewed and collected, then the correlation between hypokalemia and prognosis was determined. RESULTS: The level of serum potassium of patients ranged from 2.80 mmol/L to 4.70 mmol/L. Hypokalemia was detected in 39 out of the 81 included patients (48.15%) during hospitalization. Patients with hypokalemia had prolonged days of negative nucleic acid conversion and hospital stay. Correlation analysis showed that the level of serum potassium was negatively correlated with days of negative nucleic acid conversion and length of hospital stay. Bivariate logistic regression analysis proved that hypokalemia was a risk factor for prolonged hospital stay in patients with moderate COVID-19. CONCLUSION: Hypokalemia was prevalent in patients with moderate COVID-19 in Yangzhou, China. Hypokalemia was associated with the prolonged hospital stay in patients with moderate COVID-19.


Subject(s)
COVID-19 , Hypokalemia , Nucleic Acids , COVID-19/complications , COVID-19/epidemiology , China/epidemiology , Humans , Hypokalemia/complications , Hypokalemia/epidemiology , Potassium , Prognosis , Retrospective Studies
4.
Postgrad Med J ; 98(1160): 477-482, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1927658

ABSTRACT

Diuretic-induced hypokalaemia is a common and potentially life-threatening adverse drug reaction in clinical practice. Previous studies revealed a prevalence of 7%-56% of hypokalaemia in patients taking thiazide diuretics. The clinical manifestations of hypokalaemia due to diuretics are non-specific, varying from asymptomatic to fatal arrhythmia. Diagnosis of hypokalaemia is based on the level of serum potassium. ECG is useful in identifying the more severe consequences. A high dosage of diuretics and concomitant use of other drugs that increase the risk of potassium depletion or cardiac arrhythmias can increase the risk of cardiovascular events and mortality. Thiazide-induced potassium depletion may cause dysglycaemia. The risk of thiazide-induced hypokalaemia is higher in women and in black people. Reducing diuretic dose and potassium supplementation are the most direct and effective therapies for hypokalaemia. Combining with a potassium-sparing diuretic or blocker of the renin-angiotensin system also reduces the risk of hypokalaemia. Lowering salt intake and increasing intake of vegetables and fruits help to reduce blood pressure as well as prevent hypokalaemia.


Subject(s)
Hypertension , Hypokalemia , Arrhythmias, Cardiac/chemically induced , Diuretics/adverse effects , Female , Humans , Hypertension/chemically induced , Hypertension/complications , Hypertension/drug therapy , Hypokalemia/chemically induced , Hypokalemia/complications , Hypokalemia/drug therapy , Potassium/adverse effects , Sodium Chloride Symporter Inhibitors/adverse effects , Thiazides/adverse effects
5.
preprints.org; 2022.
Preprint in English | PREPRINT-PREPRINTS.ORG | ID: ppzbmed-10.20944.preprints202207.0394.v1

ABSTRACT

Introduction: Hydroxychloroquine (HCQ) is an antimalarial agent that has been tried out in the treatment of COVID-19, however, evidence of efficacy remains limited. Although Hydroxychloroquine overdose is not common, growing cases of poisoning with HCQ have been reported during recent years. HCQ toxicity is characterized by life-threatening symptoms which require immediate medical intervention. This report presents a suicide attempt in a hyperglycemic patient, massive ingestion of HCQ manifested by hypokalemia and acidosis.Case summaryA 47-year-old man presented at the hospital hours after massive ingestion of HCQ (100 tablets), with generalized weakness and dizziness which had led to a fall. He was drowsy and had experienced episodes of nausea/vomiting. His past medical history was remarkable for uncontrolled diabetes mellitus, confirmed by the blood glucose of 345 mg/dL, and a previous history of hospitalization a few months ago, due to a suicide attempt. He developed marked hypokalemia accompanied by acidosis, plasma potassium of 2.8 mmol/L and pH 7.34, and hypotension, blood pressure of 80/51 mm Hg, but survived with close cardiac monitoring and immediate intervention including aggressive potassium replacement, bicarbonate infusion, and charcoal administration. ConclusionConsidering the significantly increased off-label use of HCQ during the COVID-19 pandemic, this report alerts the potential for HCQ to be associated with severe electrolyte disorders, especially in predisposing conditions like diabetes. Clinicians should keep in mind the possibility of hypoglycemia in diabetic patients under hypoglycemic medications and concurrent use of chloroquine/HCQ. This therapeutic approach also suggests the benefit of even a delayed activated charcoal administration in the treatment of HCQ poisoning.


Subject(s)
Diabetes Mellitus , Muscle Weakness , Hypoglycemia , Hypotension , COVID-19 , Hyperglycemic Hyperosmolar Nonketotic Coma , Hypokalemia
7.
BMJ Case Rep ; 15(4)2022 Apr 26.
Article in English | MEDLINE | ID: covidwho-1816729

ABSTRACT

Congenital chloride losing diarrhoea (CCLD) is a rare disease caused by mutations in an intestinal chloride/bicarbonate ion exchange channel. Few reports describe CCLD in adults and none has described the impact of a parasitic infection on CCLD. Severe diarrhoea may result in hypokalaemia with QT interval prolongation. Treatment with antiemetics may further increase the QT interval. To raise awareness of this preventable complication, we describe the course of a woman in her 20s with CCLD who developed COVID-19 and a Blastocystis hominis infestation. Treatment with antiemetics and hypokalaemia resulted in prolongation of the QT interval to 640 ms. While, the QT interval normalised with discontinuation of antiemetics and electrolyte replacement, patients with CCLD must take precautions to prevent gastrointestinal infections. Regardless, whenever patients with CCLD present to hospital, the authors recommend monitoring the QT interval and avoiding medications that predispose to torsade de pointes.


Subject(s)
Antiemetics , Blastocystis hominis , COVID-19 Drug Treatment , Hypokalemia , Long QT Syndrome , Adult , Chlorides , Diarrhea/chemically induced , Diarrhea/complications , Diarrhea/congenital , Diarrhea/drug therapy , Electrocardiography , Female , Humans , Hypokalemia/complications , Long QT Syndrome/chemically induced , Long QT Syndrome/drug therapy , Metabolism, Inborn Errors
10.
J Emerg Med ; 62(3): 332-336, 2022 03.
Article in English | MEDLINE | ID: covidwho-1624787

ABSTRACT

BACKGROUND: Hydroxychloroquine overdose is rare but potentially lethal. Hydroxychloroquine overdose symptoms are characterized by central nervous system toxicity, cardiac toxicity, and hypokalemia. Recommended treatment consists of epinephrine, high-dose diazepam, and careful potassium repletion. Few pediatric hydroxychloroquine overdoses have been reported. CASE REPORT: We describe a 14-year-old girl who ingested 10 g (172 mg/kg) of hydroxychloroquine. She developed tachycardia, hypotension, and hypokalemia. She was intubated and treated with diazepam and epinephrine infusions and potassium supplementation. Her serum hydroxychloroquine concentration obtained 10 h after ingestion was 13,000 ng/mL (reference range 500-2000 ng/mL). The patient made a full medical recovery. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Pediatric hydroxychloroquine overdoses are reported rarely, and the toxic and lethal doses of hydroxychloroquine ingestion have not been established. This case of a teenaged patient who ingested 10 g of hydroxychloroquine and survived provides additional information that may be used to help establish toxic and lethal doses of ingestion.


Subject(s)
Drug Overdose , Hypokalemia , Adolescent , Child , Diazepam/therapeutic use , Drug Overdose/drug therapy , Eating , Epinephrine/therapeutic use , Female , Humans , Hydroxychloroquine/adverse effects , Potassium/therapeutic use
11.
researchsquare; 2022.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-1240319.v1

ABSTRACT

Background: In the light of recent years, an increase in the number of life-threatening infections due to various fungi has been observed, especially in tertiary care centers. With Amphotericin B labelled as the first choice in treating these infections, one of its common side effects, nephrotoxicity, along with hypokalemia, were studied to determine the epidemiology, risk factors, and protective measures. Method: ology: The study was a retrospective observational chart review study in which patients were receiving conventional Amphotericin B in two tertiary hospitals in Palestine from January 2018 to December 2020 were evaluated for the development of hypokalemia and nephrotoxicity; according to the KDIGO criteria. A total of 117 patients were included in the study. Patients who have received the drug intermittently, in fewer than two doses, through non-IV routes and patients under the age of 12 were excluded. The data collected included, but were not limited to, age, gender, comorbidities, Amphotericin B treatment details, medications, COVID-19 status, risk factors, and hypothesized protective measures. Results: : The incidence of conventional Amphotericin B nephrotoxicity and hypokalemia was 46% and 33%, respectively. With a roughly equal representation of both genders and a median age of 52 years in a range of 13-89. No association between the variables and the development of nephrotoxicity was found.; However, a 3.4 increased risk (p-value=0.01) of developing hypokalemia in females compared to males was observed. Conclusion: Our research has shown a relatively lower, yet consistent, incidence of conventional amphotericin B nephrotoxicity and hypokalemia compared to literature with gender being a risk factor for developing hypokalemia.


Subject(s)
COVID-19 , Aphasia, Conduction , Hypokalemia
12.
Br J Pharmacol ; 179(11): 2631-2646, 2022 06.
Article in English | MEDLINE | ID: covidwho-1537801

ABSTRACT

BACKGROUND AND PURPOSE: Hydroxychloroquine, chloroquine and azithromycin are three drugs that were proposed to treat coronavirus disease 2019 (COVID-19). While concern already existed around their proarrhythmic potential, there are little data regarding how altered physiological states encountered in patients such as febrile state, electrolyte imbalances or acidosis might change their risk profiles. EXPERIMENTAL APPROACH: Potency of human ether-à-go-go related gene (hERG) block was measured using high-throughput electrophysiology in the presence of variable environmental factors. These potencies informed simulations to predict population risk profiles. Effects on cardiac repolarisation were verified in human induced pluripotent stem cell-derived cardiomyocytes from multiple individuals. KEY RESULTS: Chloroquine and hydroxychloroquine blocked hERG with IC50 of 1.47 ± 0.07 and 3.78 ± 0.17 µM, respectively, indicating proarrhythmic risk at concentrations effective against severe acute respiratory syndrome-coronovirus-2 (SARS-CoV-2) in vitro. Hypokalaemia and hypermagnesaemia increased potency of chloroquine and hydroxychloroquine, indicating increased proarrhythmic risk. Acidosis significantly reduced potency of all drugs, whereas increased temperature decreased potency of chloroquine and hydroxychloroquine against hERG but increased potency for azithromycin. In silico simulations demonstrated that proarrhythmic risk was increased by female sex, hypokalaemia and heart failure and identified specific genetic backgrounds associated with emergence of arrhythmia. CONCLUSION AND IMPLICATIONS: Our study demonstrates how proarrhythmic risk can be exacerbated by metabolic changes and pre-existing disease. More broadly, the study acts as a blueprint for how high-throughput in vitro screening, combined with in silico simulations, can help guide both preclinical screening and clinical management of patients in relation to drugs with potential to prolong repolarisation.


Subject(s)
Acidosis , COVID-19 Drug Treatment , Hypokalemia , Induced Pluripotent Stem Cells , Acidosis/chemically induced , Acidosis/drug therapy , Azithromycin/adverse effects , Chloroquine/adverse effects , Female , Humans , Hydroxychloroquine/adverse effects , Hypokalemia/chemically induced , SARS-CoV-2
13.
J Dev Behav Pediatr ; 43(5): e356-e360, 2022.
Article in English | MEDLINE | ID: covidwho-1503706

ABSTRACT

OBJECTIVE: Pediatric patients with autism spectrum disorder (ASD) often have coexisting feeding disorders. We hope to emphasize the significant implications that these feeding disorders can have on this patient population through a unique case of hypokalemia-induced rhabdomyolysis. METHOD: We present a unique case of a 3-year-old boy with ASD and a longstanding history of food selectivity whose routine was disrupted during the COVID-19 pandemic resulting in avoidant/restrictive food intake disorder and severe undernutrition, who presented with profound hypokalemia and was subsequently found to have elevated muscle enzymes consistent with rhabdomyolysis despite only subtle complaints of difficulty walking. RESULTS: The patient was treated with aggressive hydration, electrolyte therapy, and nasogastric tube feeds, which resulted in clinical and biochemical evidence of improvement. He was also reconnected to ASD-related care services that had lapsed during the COVID-19 pandemic. CONCLUSION: This case exemplifies the adverse impact that feeding disorders can have on patients with ASD, particularly in the setting of stressors such as a global pandemic, and is also the first documented pediatric case of rhabdomyolysis secondary to hypokalemia from severe undernutrition. It demonstrates that physicians should have a low threshold to assess for clinical and laboratory evidence of rhabdomyolysis in patients with profound hypokalemia because symptoms of hypokalemia-induced rhabdomyolysis can often be subtle, which can delay diagnosis and thereby increase the risk for life-threatening complications from extensive muscle damage.


Subject(s)
Autism Spectrum Disorder , Autistic Disorder , COVID-19 , Hypokalemia , Malnutrition , Rhabdomyolysis , Autism Spectrum Disorder/complications , COVID-19/complications , Child , Child, Preschool , Humans , Hypokalemia/chemically induced , Hypokalemia/complications , Male , Malnutrition/complications , Pandemics , Rhabdomyolysis/chemically induced , Rhabdomyolysis/therapy
14.
Rev Med Virol ; 32(1): e2262, 2022 01.
Article in English | MEDLINE | ID: covidwho-1252048

ABSTRACT

Coronavirus disease (Covid-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently the largest health crisis facing most countries. Several factors have been linked with a poor prognosis for this disease, including demographic factors, pre-existing comorbidities and laboratory parameters such as white blood cell count, D-dimer, C-reactive protein, albumin, lactate dehydrogenase, creatinine and electrolytes. Electrolyte abnormalities particularly potassium disorders are common among Covid-19 patients. Based on our pooled analysis, hypokalemia and hyperkalemia occur in 24.3% and 4.15% of Covid-19 patients, respectively. Potassium level deviation from the normal range may increase the chances of unfavorable outcomes and even death. Therefore, this article reviewed the epidemiology of potassium disorders and explained how hypokalemia and hyperkalemia are capable of deteriorating cardiac outcomes and the prognosis of Covid-19 for infected patients. The article finishes by highlighting some important considerations in the management of hypokalemia and hyperkalemia in these patients.


Subject(s)
COVID-19/complications , Hyperkalemia/therapy , Hypokalemia/therapy , Potassium/blood , Biomarkers/blood , COVID-19/blood , Humans , Hyperkalemia/blood , Hyperkalemia/epidemiology , Hyperkalemia/virology , Hypokalemia/blood , Hypokalemia/epidemiology , Hypokalemia/virology , Prognosis , SARS-CoV-2
15.
Biomed Res Int ; 2021: 6667047, 2021.
Article in English | MEDLINE | ID: covidwho-1186382

ABSTRACT

The novel coronavirus disease 2019 (COVID-19) is the cause of an acute respiratory illness which has spread around the world. The virus infects the host by binding to the angiotensin-converting enzyme 2 (ACE2) receptors. Due to the presence of ACE2 receptors in the kidneys and gastrointestinal (GI) tract, kidneys and GI tract damage arising from the virus can be seen in patients and can cause acute conditions such as acute kidney injury (AKI) and digestive problems for the patient. One of the complications of kidneys and GI involvement in COVID-19 is fluid and electrolyte disturbances. The most common ones of these disorders are hyponatremia, hypernatremia, hypokalemia, hypocalcemia, hypochloremia, hypervolemia, and hypovolemia, which if left untreated, cause many problems for patients and even increase mortality. Fluid and electrolyte disturbances are more common in hospitalized and intensive care patients. Children are also at greater risk for fluid and electrolyte disturbances complications. Therefore, clinicians should pay special attention to the fluid and electrolyte status of patients. Changes in fluid and electrolyte levels can be a good indicator of disease progression.


Subject(s)
Body Fluids/metabolism , COVID-19/etiology , Electrolytes/metabolism , Acute Kidney Injury/etiology , COVID-19/complications , Gastrointestinal Tract/physiopathology , Gastrointestinal Tract/virology , Humans , Hypocalcemia/etiology , Hypokalemia/etiology , Hyponatremia/etiology , Kidney/physiopathology , Kidney/virology
16.
authorea preprints; 2021.
Preprint in English | PREPRINT-AUTHOREA PREPRINTS | ID: ppzbmed-10.22541.au.161684943.32764821.v1

ABSTRACT

Background: - Since SARS-CoV-2 spread, evidences regarding sex differences in progression and prognosis of COVID-19 have emerged. Besides this, studies on patients’ clinical characteristics have described electrolyte imbalances as one of the recurrent features of COVID-19. Methods - We performed a case-control study on all patients admitted to the emergency department (ED) from 1st March to 31st May 2020 who had undergone a blood gas analysis and a nasopharyngeal swab test for SARS-CoV-2 by rtPCR. We defined positive patients as cases and negatives as controls. The study was approved by the local ethics committee Area 3 Milan. Data were automatically extracted from the hospital laboratory SQL-based repository in anonymized form. We considered as outcomes potassium (K+), sodium (Na+), chlorine (Cl-) and calcium (Ca++) as continuous and as categorical variables, in their relation with age, sex and SARS-CoV-2 infection status. Results - We observed a higher prevalence of hypokalemia among patients positive for SARS-CoV-2 (13.7% vs 6% of negative subjects). Positive patients had a higher probability to be admitted to the ED with hypokalemia (OR 2.75, 95% CI 1.8-4.1 p<0.0001) and women were twice as likely to be affected than men (OR 2.43, 95% CI 1.67-3.54 p<0.001). Odds ratios for positive patients to manifest with an alteration in serum Na+ was (OR 1.6, 95% CI 1.17-2.35 p<0.001) and serum chlorine (OR 1.6, 95% CI 1.03-2.69 p<0.001). Notably, OR for positive patients to be hypocalcemic was 7.2 (95% IC 4.8-10.6 p<0.0001) with a low probability for women to be hypocalcemic (OR 0.63, 95% IC 0.4-0.8 p=0.005). Conclusions - SARS-CoV-2 infection is associated with a higher prevalence of hypokalemia, hypocalcemia, hypochloremia and sodium alterations. Hypokalemia is more frequent among women and hypocalcemia among men.


Subject(s)
COVID-19 , Emergencies , Hypokalemia , Hypocalcemia
17.
Mil Med ; 186(9-10): e1053-e1057, 2021 08 28.
Article in English | MEDLINE | ID: covidwho-1135872

ABSTRACT

We report the case of a 52-year-old white male who was recently diagnosed with symptomatic coronavirus disease-2019 (COVID-19) and presented to the hospital with ventricular tachycardia/ventricular fibrillation cardiac arrest, ST elevation myocardial infarction, and profound hypokalemia. The patient was successfully treated with primary percutaneous coronary intervention and concurrent aggressive potassium repletion. To the authors' knowledge, this is the first case of COVID-19 presenting not only with an acute coronary thrombosis but also severe hypokalemia, both of which contributed to his cardiac arrest. The association of COVID-19 with acute coronary thrombosis, including the challenges surrounding the diagnosis and management in this patient population, is discussed. Additionally, the effect of COVID-19 on the renin-angiotensin-aldosterone system is reviewed with a focus on hypokalemic presentations.


Subject(s)
COVID-19 , Coronary Thrombosis , Hypokalemia , Percutaneous Coronary Intervention , ST Elevation Myocardial Infarction , Humans , Hypokalemia/complications , Male , Middle Aged , SARS-CoV-2 , ST Elevation Myocardial Infarction/complications
18.
Hipertens Riesgo Vasc ; 38(3): e10-e12, 2021.
Article in Spanish | MEDLINE | ID: covidwho-1131316

ABSTRACT

Liquorice is one of the oldest known herbs with medicinal properties and comprises up to 300 active compounds. It has been used for millennia for its digestive, anti-inflammatory and anti-infective properties. However, its possible toxic effects were described only a few years ago and there is growing interest in the side effects associated with chronic consumption. The main active component of liquorice is the prodrug glycyrrhizin and its active metabolite glycyrrhetic acid. It is a rare cause of hypokalaemia due to suppression of the renin-angiotensin-aldosterone axis, causing pseudohyperaldostenonism (PHA). We describe a rare case of secondary acute myocardial infarction in a patient with chronic consumption of liquorice.


Subject(s)
COVID-19 , Glycyrrhetinic Acid/adverse effects , Glycyrrhiza , Hypokalemia/chemically induced , Myocardial Infarction/chemically induced , Quarantine , Substance-Related Disorders/complications , Aged, 80 and over , Female , Humans , Severity of Illness Index
19.
Encephale ; 46(3S): S93-S98, 2020 Jun.
Article in French | MEDLINE | ID: covidwho-1065058

ABSTRACT

Although the "panic" word has been abundantly linked to the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic in the press, in the scientific literature very few studies have considered whether the current epidemic could predispose to the onset or the aggravation of panic attacks or panic disorder. Indeed, most studies thus far have focused on the risk of increase and aggravation of other psychiatric disorders as a consequence of the SARS-CoV-2 epidemic, such as obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and generalized anxiety disorder (GAD). Yet, risk of onset or aggravation of panic disorder, especially the subtype with prominent respiratory symptoms, which is characterized by a fear response conditioning to interoceptive sensations (e.g., respiratory), and hypervigilance to these interoceptive signals, could be expected in the current situation. Indeed, respiratory symptoms, such as coughs and dyspnea, are among the most commonly associated with the SARS-CoV-2 (59-82% and 31-55%, respectively), and respiratory symptoms are associated with a poor illness prognosis. Hence given that some etiological and maintenance factors associated with panic disorder - i.e., fear conditioning to abnormal breathing patterns attributable or not to the COVID-19 (coronavirus disease 2019), as well as hypervigilance towards breathing abnormalities - are supposedly more prevalent, one could expect an increased risk of panic disorder onset or aggravation following the COVID-19 epidemic in people who were affected by the virus, but also those who were not. In people with the comorbidity (i.e., panic disorder or panic attacks and the COVID-19), it is particularly important to be aware of the risk of hypokalemia in specific at-risk situations or prescriptions. For instance, in the case of salbutamol prescription, which might be overly used in patients with anxiety disorders and COVID-19, or in patients presenting with diarrhea and vomiting. Hypokalemia is associated with an increased risk of torsade de pointe, thus caution is required when prescribing specific psychotropic drugs, such as the antidepressants citalopram and escitalopram, which are first-line treatments for panic disorder, but also hydroxyzine, aiming at anxiety reduction. The results reviewed here highlight the importance of considering and further investigating the impact of the current pandemic on the diagnosis and treatment of panic disorder (alone or comorbid with the COVID-19).


Subject(s)
Betacoronavirus , Coronavirus Infections/psychology , Pandemics , Panic Disorder/psychology , Pneumonia, Viral/psychology , Anxiety/etiology , Anxiety/psychology , Anxiety Disorders/drug therapy , Anxiety Disorders/epidemiology , Anxiety Disorders/physiopathology , Anxiety Disorders/psychology , COVID-19 , Catastrophization , Comorbidity , Coronavirus Infections/epidemiology , Dyspnea/etiology , Dyspnea/psychology , Female , Humans , Hypokalemia/etiology , Male , Panic Disorder/drug therapy , Panic Disorder/epidemiology , Panic Disorder/physiopathology , Pneumonia, Viral/epidemiology , Psychotropic Drugs/adverse effects , Psychotropic Drugs/therapeutic use , Renin-Angiotensin System/physiology , Respiration/drug effects , SARS-CoV-2 , Stress, Psychological/etiology , Stress, Psychological/physiopathology , Terminology as Topic , Torsades de Pointes/chemically induced , Torsades de Pointes/etiology
SELECTION OF CITATIONS
SEARCH DETAIL